CepTor CORP Form 8-K October 12, 2006

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) <u>October 12, 2006</u> CepTor Corporation

(Exact Name of Registrant as Specified in Its Charter) Delaware

(State or Other Jurisdiction of Incorporation)

001-32496

(Commission File Number)

200 International Circle, Suite 5100 Hunt Valley, Maryland

(Address of Principal Executive Offices)

(410) 527-9998

(Registrant s Telephone Number, Including Area Code) Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

(IRS Employer Identification No.)

21030-1350 (Zip Code)

11-2897392

Item 8.01 Other Events.

On October 12, 2006, CepTor Corporation (the Company) issued a press release disclosing that the results of testing Neurodur in the Experimental Autoimmune Encephalomyelitis (EAE) mouse model (the standard animal model used in multiple sclerosis (MS) testing) were published in the *Journal of Neuroimmunology* and that the data indicated that the reduction of clinical symptoms of MS in EAE mice treated with oral Neurodur were statistically significant. **Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits

Exhibit No.99.1Press Release

Description

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CEPTOR CORPORATION

Date: October 12, 2006

By: /s/ William H. Pursley William H. Pursley Chairman and Chief Executive Officer

EXHIBIT INDEX

Exhibit No.

99.1 Press Release

Description